Note: This document contains side effect information about nizatidine. Some of the dosage forms listed on this page may not apply to the brand name Axid AR.
Applies to nizatidine: oral capsules, oral tablets for
Side effects include:
Applies to nizatidine: oral capsule, oral solution, oral tablet
The most commonly reported side effects included headache, rhinitis, abdominal pain, and diarrhea.
Very common (10% or more): Headache (up to 16.6%)
Common (1% to 10%): Dizziness, somnolence
Frequency not reported: Seizure
A pediatric patient given 2.5 mg/kg orally 2 times a day for 23 days experienced an EEG-diagnosed seizure during treatment.
Common (1% to 10%): Constipation, diarrhea, dry mouth, dyspepsia, flatulence, gastrointestinal disorder, nausea, nausea and vomiting, tooth disorder, vomiting
Common (1% to 10%): Cough, cough increased, nasal congestion, nasopharyngitis, pharyngitis, rhinitis, sinusitis
Postmarketing reports: Bronchospasm, laryngeal edema
Common (1% to 10%): Accident, asthenia, fever, injury, pain, pyrexia, surgical procedure
Common (1% to 10%): Abnormal dreams, anxiety, insomnia, irritability, nervousness
Postmarketing reports: Decreased libido, reversible mental confusion
Common (1% to 10%): Pruritus, rash, sweating, urticaria
Postmarketing reports: Exfoliative dermatitis
Common (1% to 10%): Back pain, myalgia
Postmarketing reports: Arthralgia
Common (1% to 10%): Infection
Rare (0.01% to 0.1%): Serum sickness, serum sickness-like reactions
Common (1% to 10%): Chest pain
Frequency not reported: Short episodes of asymptomatic ventricular tachycardia
Postmarketing reports: Vasculitis
Common (1% to 10%): Anorexia
Postmarketing reports: Hyperuricemia unrelated to gout or nephrolithiasis
Common (1% to 10%): Amblyopia
Fatal thrombocytopenia was reported in a patient who experienced possible drug-related thrombocytopenia previously received this drug and another histamine-2 (H2) receptor antagonist.
Uncommon (0.1% to 1%): Anemia
Postmarketing reports: Agranulocytosis, eosinophilia, fatal thrombocytopenia, leukopenia, thrombocytopenic purpura
Rare (0.01% to 0.1%): Transient, marked transaminase elevations, transient, marked alkaline phosphatase elevations
Frequency not reported: Elevated liver enzyme tests (alkaline phosphatase, ALT, AST), hepatocellular injury, transient, asymptomatic transaminase elevations, transient, asymptomatic alkaline phosphatase elevations
Postmarketing reports: Cholestatic injury, cholestatic injury with jaundice, hepatitis, jaundice, mixed hepatocellular injury, mixed hepatocellular injury with jaundice
Some patients developed ALT and/or AST elevations exceeding 500 international units/L, with a report of an ALT level exceeding 2000 international units/L.
Some patients 2 to 18 years developed mild elevations in serum transaminase levels (1 to 2 times the upper limit of normal).
Liver enzyme elevations and liver abnormalities were reversible upon discontinuation of treatment.
Hypersensitivity reactions included bronchospasm, eosinophilia, laryngeal edema, and rash.
Postmarketing reports: Anaphylaxis, hypersensitivity reactions
Postmarketing reports: Impotence
Postmarketing reports: Gynecomastia
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Axid